Diplomat Pharmacy

Diplomat is a nationally recognized specialty pharmacy, and here, we offer a special kind of care. At Diplomat, we blend clinical excellence with a personal touch, providing medications and support to people with serious long-term diseases, including cancer, multiple sclerosis, HIV and rheumatoid arthritis. Through our partnerships, we offer specialty care in retail pharmacies across the U.S. and grant specialty-care coverage to millions of lives nationwide.

MAITLAND, Fla.--(BUSINESS WIRE)--Advanced Dermatology and Cosmetic Surgery (ADCS), one of the nation’s leaders in high-quality dermatology, today announced the appointment of Daniel Davison as Chief Financial Officer. Mr. Davison was most recently Chief Financial Officer and Treasurer at Diplomat Pharmacy, Inc. (NYSE: DPLO), which was the largest independent provider of specialty pharmacy services in the United States. Mr. Davison has broad financial management experience, including both operat

Daniel Davison Joins Advanced Dermatology and Cosmetic Surgery as Chief Financial Officer

The beleaguered specialty pharmacy is being "taken under."

Why Diplomat Pharmacy Crashed (for a Final Time?) Today

UnitedHealth Group

UnitedHealth Group’s Optum unit will buy the specialty pharmacy Diplomat for $300 million and combine it with OptumRx.

UnitedHealth’s Optum To Buy Diplomat Specialty Pharmacy For $300M

Diplomat Pharmacy (NYSE: DPLO) shares are trading lower on Monday after the company received a $4 per share acquisition offer from UnitedHealth Group's (NYSE: UNH) OptumRx.

UnitedHealth To Buy Diplomat Pharmacy For $300M

UnitedHealth Group's OptumRx pharmacy care services unit is acquiring specialty pharmacy Diplomat Pharmacy Inc.

UnitedHealth's Optum to acquire Diplomat Pharmacy for $4 a share in cash

Investors need to pay close attention to Diplomat Pharmacy (DPLO) stock based on the movements in the options market lately.

Implied Volatility Surging for Diplomat Pharmacy (DPLO) Stock Options

More volatility for the beleaguered specialty pharmacy and pharmacy benefit manager.

Here's Why Diplomat Pharmacy Jumped Higher Today

Volatility plagues the specialty pharmacy and pharmacy benefit manager.

Here’s Why Diplomat Pharmacy Stock Bounced Back 14% Today

Diplomat Pharmacy Inc (NYSE: DPLO) cautioned investors on Tuesday that it has "substantial doubts" related to its ability to continue functioning as a business.

Diplomat Pharmacy Analysts Weigh Takeout Scenarios, Valuation After Going Concern Warning

Shares of Diplomat Pharmacy, Inc. (NYSE: DPLO), a Flint, Michigan-based independent provider of specialty pharmacy and infusion services, plummeted more than 50% Tuesday after the company warned investors it faces an existential threat.

Diplomat Pharmacy Has 'Substantial Doubt' It Can Continue Operations

Diplomat Pharmacy's (DPLO) CEO Brian Griffin on Q3 2019 Results - Earnings Call Transcript

The loss of a major contract is a serious blow.

Here's Why Diplomat Pharmacy Got Hammered Today

Diplomat Pharmaceuticals (DPLO) delivered earnings and revenue surprises of -40.00% and 11.81%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Diplomat Pharmaceuticals (DPLO) Reports Q3 Loss, Tops Revenue Estimates

The company is undergoing a review of strategic alternatives.

Diplomat Pharmacy Considers Its Options

Diplomat Pharmacy's (DPLO) CEO Brian Griffin on Q2 2019 Results - Earnings Call Transcript

Shares of Diplomat Pharmacy Inc. DPLO, +3.91% rallied 5.3% in premarket trading Friday, after the provider of specialty pharmacy and infusion services said it was considering a potential sale of the company, while reporting a wider second-quarter loss and increased its full-year loss guidance.

Diplomat Pharmacy's stock climbs after potential sale considered as it reported a wider loss

Diplomat Pharmacy, Inc. (NYSE: DPLO) reported second-quarter earnings at $2.13 per share.

Diplomat Pharmacy Reports Q2 Earnings Beat, Will Explore Strategic Alternatives

Diplomat Pharmaceuticals (DPLO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Diplomat Pharmaceuticals (DPLO) to Report a Decline in Earnings: What to Look Out for

It'll be a few months before the company can secure new clients for its pharmacy benefit manager business.

Waiting on Diplomat Pharmacy to Rebuild

Diplomat Pharmacy, Inc. (DPLO) CEO Brian Griffin on Q1 2019 Results - Earnings Call Transcript

Diplomat Pharmaceuticals (DPLO) delivered earnings and revenue surprises of -371.43% and 8.43%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Diplomat Pharmaceuticals (DPLO) Reports Q1 Loss, Tops Revenue Estimates

Diplomat Pharmaceuticals (DPLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Diplomat Pharmaceuticals (DPLO) Expected to Beat Earnings Estimates: Should You Buy?

Diplomat Pharmacy Inc shares nosedived Feb.

Diplomat Pharmacy's Valuation Presents Value To A Strategic Buyer, Raymond James Says In Upgrade

Some stumbles will make this a challenging year for the specialty pharmacy.

Diplomat Pharmacy Looks to Rebuild

Diplomat Pharmacy Inc on Friday reported its previously delayed fourth-quarter earnings miss and concerning guidance, which sent the stock tumbling nearly 14 percent.

News for Diplomat Pharmacy Stock (DPLO)